Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Although patients with amnestic mild cognitive impairment (aMCI) are at higher risk of developing Alzheimer's disease (AD), their pathologies could be heterogeneous. We aimed to evaluate structural changes in amyloid-negative and amyloid-positive aMCI patients. Forty-eight aMCI patients who underwent Pittsburgh compound B (PiB) positron emission tomography were recruited. They were classified as PiB (-) aMCI (N = 16) and PiB (+) (N = 32). Hippocampal shape and regional cortical thickness were compared with 41 subjects with normal cognition (NC). Relative to NC, PiB(-) aMCI exhibited hippocampal deformity in the right cornu ammonis 1, whereas PiB(+) aMCI exhibited hippocampal deformity in bilateral subiculum and cornu ammonis 1 subregions. Relative to NC, PiB(-) aMCI showed cortical thinning in the left medial prefrontal and right anterior temporal regions, whereas PiB(+) aMCI exhibited cortical thinning in bilateral medial temporal regions, temporoparietal junctions and precuneus, and prefrontal cortices. Our findings suggest that structural changes in PiB(-) aMCI might be due to several possible pathologic changes, whereas structural changes in PiB(+) aMCI reflect AD-like structural changes.

Original publication

DOI

10.1016/j.neurobiolaging.2013.08.017

Type

Journal article

Journal

Neurobiol Aging

Publication Date

02/2014

Volume

35

Pages

291 - 300

Keywords

Alzheimer's disease, Cortical thickness, Hippocampus, Mild cognitive impairment, Pittsburgh compound B, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Atrophy, Cerebral Cortex, Cognitive Dysfunction, Female, Hippocampus, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Positron-Emission Tomography, Prospective Studies, Radiopharmaceuticals, Risk, Thiazoles